Iloprost is a synthetic prostacyclin analogue used in the treatment of pulmonary arterial hypertension, where it acts as a potent vasodilator of systemic and pulmonary arterial vascular beds. This category… Read more

![Chemical structure of (3'aS,4'R,5'R,6'aR)-Hexahydro-5'-hydroxy-5,5-dimethyl-spiro[1,3-dioxane-2,2'(1'H)-pentalene]-4'-carboxylic acid methyl ester](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F118375-00-1-3aS4R5R6aR-Hexahydro-5-hydroxy-55-dimethyl-spiro13-dioxane-221H-pentalene-4-carboxylic-acid-methyl-ester.png&w=3840&q=75)
![Chemical structure of (3aR,4R,5R,6aS)-5-Hydroxy-4-(hydroxymethyl)hexahydro-2H-cyclopenta[b]furan-2-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F159812-79-0-3aR4R5R6aS-5-Hydroxy-4-hydroxymethylhexahydro-2H-cyclopentabfuran-2-one.png&w=3840&q=75)








Iloprost is a synthetic prostacyclin analogue used in the treatment of pulmonary arterial hypertension, where it acts as a potent vasodilator of systemic and pulmonary arterial vascular beds. This category contains the active pharmaceutical ingredient alongside its related compounds, including synthetic intermediates, key stereoisomers, and various process-related impurities essential for impurity profiling. Laboratories utilize these high-quality reference standards for rigorous method validation, routine quality control, and testing of drug formulations. Furthermore, stable isotope labelled compounds, such as deuterated variants, are available to serve as internal standards in analytical testing and mass spectrometry-based quantification. These materials provide the necessary analytical support to ensure the safety, efficacy, and consistency of pharmaceutical products throughout the manufacturing and development lifecycle.